Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma Academic Article uri icon

Overview

MeSH Major

  • Carcinoma, Renal Cell
  • Indoles
  • Interferon-alpha
  • Kidney Neoplasms
  • Pyrroles

abstract

  • Sunitinib demonstrates longer overall survival compared with IFN-alpha plus improvement in response and progression-free survival in the first-line treatment of patients with metastatic RCC. The overall survival highlights an improved prognosis in patients with RCC in the era of targeted therapy.

publication date

  • August 2009

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3646307

Digital Object Identifier (DOI)

  • 10.1200/JCO.2008.20.1293

PubMed ID

  • 19487381

Additional Document Info

start page

  • 3584

end page

  • 90

volume

  • 27

number

  • 22